Physician profile
Howard Belfer
NPI 1740206457
$3,789.93
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,533 · 2020: $921 · 2021: $1,335.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $515.05 | 2019-2021 | |
| Sk Life Science, INC. | $456.52 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $450.69 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $366.31 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $358.06 | 2019-2021 | |
| Amgen INC. | $328.92 | 2019-2021 | |
| Eisai INC. | $308.67 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $162.35 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $152.77 | 2020-2021 | |
| Ucb, INC. | $142.00 | 2019-2021 | |
| Abbvie INC. | $128.76 | 2021 | |
| Acorda Therapeutics, INC | $77.18 | 2019 | |
| Kyowa Kirin, INC. | $72.36 | 2019-2021 | |
| Emd Serono, INC. | $60.46 | 2019 | |
| Lilly USA, LLC | $52.61 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.37 | 2020 | |
| Bausch Health US, LLC | $35.92 | 2019 | |
| Pfizer INC. | $26.70 | 2019 | |
| Tanabe Pharma America, INC. | $26.50 | 2019 | |
| Biogen, INC. | $19.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Belfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.